Tag Archives: Randal Mills

Business, Finance, Occupation & Industry

Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NAS: OSIR) , the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2013 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 19, 2013 at 9:30 a.m. ET (8:30 a.m. CT) in Chicago.

A live webcast of the presentation may be accessed through the Investors page of the Company’s website at www.Osiris.com. A replay of the webcast will be available for one week following the conference. Also, if in Chicago, please visit Osiris at booth 207 of McCormick Place for the Annual Meeting of The American Academy of Orthopaedic Surgeons, March 20-22.

About Osiris Therapeutics

Osiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal®, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix® for acute and chronic wounds, and Ovation® and Cartiform for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of cellular products. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology, including 50 U.S. and 156 foreign patents.

Osiris, Prochymal, Chondrogen, Grafix and Ovation are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company’s website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NAS: OSIR) the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the fourth quarter and full year ended December 31, 2012.

Recent and Full Year Highlights

  • Achieved world’s first approval for a stem cell drug from Health Canada to market Prochymal® (remestemcel-L) for the treatment of acute graft versus host disease (GvHD) in children.
  • Established and deployed a direct sales force for Grafix®, a premium cellular repair matrix for serious wounds including diabetic foot ulcers, in 10 major metropolitan areas throughout the United States.
  • Launched CartiformTM, viable cartilage mesh for the treatment of articular cartilage injury.
  • Attained transitional pass-through status from the Center for Medicare & Medicaid Services (CMS) for Grafix, with Healthcare Common Procedure Coding System (HCPCS) C-Codes being designated and assignment of permanent HCPCS Q-codes.
  • Gross margin improved 12 percentage points to 70% with gross profit increasing to $2.1M for the quarter.
  • Reported product revenue of $7.8 million in 2012- representing a 520% increase over the prior year and 4Q12 revenue increasing 36% over 3Q12.
  • Reported year-end cash, receivables, and short-term investments of $37.2 million.

“With the approval of Prochymal, 2012 was an historic year for the entire field of stem cell medicine,” said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. “For Osiris, it was also a year of commercial transformation, having four products on the market and expanding capabilities in development, manufacturing, sales and marketing. Osiris is now a fully integrated commercial cell therapy company, well-positioned for future growth.”

Fourth Quarter Financial Results

Revenues during the fourth quarter of 2012 were $3.1 million, including Biosurgery product revenues of $2.9 million compared to $0.8 million over the same period of 2011. Gross margin during the fourth quarter was 70% compared to 58% …read more
Source: FULL ARTICLE at DailyFinance